ATE370229T1 - Ein verstärkter, durch viren vermittelter dna- transfer - Google Patents

Ein verstärkter, durch viren vermittelter dna- transfer

Info

Publication number
ATE370229T1
ATE370229T1 AT95914912T AT95914912T ATE370229T1 AT E370229 T1 ATE370229 T1 AT E370229T1 AT 95914912 T AT95914912 T AT 95914912T AT 95914912 T AT95914912 T AT 95914912T AT E370229 T1 ATE370229 T1 AT E370229T1
Authority
AT
Austria
Prior art keywords
cells
fibronectin
hematopoietic
mediated dna
dna transfer
Prior art date
Application number
AT95914912T
Other languages
English (en)
Inventor
David A Williams
Vikram P Patel
Original Assignee
Univ Indiana Res & Tech Corp
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp, Univ Northwestern filed Critical Univ Indiana Res & Tech Corp
Application granted granted Critical
Publication of ATE370229T1 publication Critical patent/ATE370229T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
AT95914912T 1994-03-25 1995-03-27 Ein verstärkter, durch viren vermittelter dna- transfer ATE370229T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/218,355 US5686278A (en) 1994-03-25 1994-03-25 Methods for enhanced retrovirus-mediated gene transfer

Publications (1)

Publication Number Publication Date
ATE370229T1 true ATE370229T1 (de) 2007-09-15

Family

ID=22814775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914912T ATE370229T1 (de) 1994-03-25 1995-03-27 Ein verstärkter, durch viren vermittelter dna- transfer

Country Status (13)

Country Link
US (1) US5686278A (de)
EP (2) EP1862546A1 (de)
JP (4) JP3411039B2 (de)
KR (2) KR100506570B1 (de)
CN (3) CN100567488C (de)
AT (1) ATE370229T1 (de)
AU (1) AU690667B2 (de)
CA (1) CA2185712C (de)
DE (1) DE69535560T2 (de)
ES (1) ES2294781T3 (de)
RU (1) RU2174846C2 (de)
TW (1) TWI232884B (de)
WO (1) WO1995026200A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9101680A (nl) 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US7083979B1 (en) * 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US6033907A (en) * 1995-09-29 2000-03-07 Indiana University Foundation Enhanced virus-mediated DNA transfer
EP0873049B1 (de) * 1995-09-29 2006-05-10 Indiana University Research and Technology Corporation Verfahren zum verbesserten virusvermittelten dns-transfer unter verwendung von molekülen mit virus- und zellbindenden domänen
WO1997018318A1 (fr) 1995-11-13 1997-05-22 Takara Shuzo Co., Ltd. Procede d'introduction de genes dans des cellules cibles au moyen de retrovirus
CA2279675A1 (en) 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for localizing a nucleic acid construct within a cell for therapeutic and diagnostic uses
JP3683912B2 (ja) * 1996-07-10 2005-08-17 タカラバイオ株式会社 細胞組成物
AU6424498A (en) * 1997-03-18 1998-10-12 Introgene B.V. Methods and compositions for genetically modifying primate bone marrow cells
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
WO2000001836A1 (en) * 1998-07-01 2000-01-13 Takara Shuzo Co., Ltd. Gene transfer methods
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
EP1163912B1 (de) * 1999-03-23 2007-10-31 Takara Bio Inc. Gentherapeutika
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
TWI317285B (en) * 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
WO2003028768A1 (fr) * 2001-09-12 2003-04-10 Takara Bio Inc. Traitements
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
FI20050753A7 (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
JP5546716B2 (ja) 2004-09-29 2014-07-09 タカラバイオ株式会社 レトロウイルスベクター産生用細胞
KR101174341B1 (ko) * 2005-02-07 2012-08-16 다카라 바이오 가부시키가이샤 레트로 바이러스의 보존 방법
WO2006101629A2 (en) * 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
WO2006134871A1 (ja) 2005-06-15 2006-12-21 Takara Bio Inc. 脂肪細胞あるいは前駆脂肪細胞への遺伝子導入方法
KR101272896B1 (ko) 2005-08-16 2013-06-25 다카라 바이오 가부시키가이샤 면역 결핍 바이러스 감염의 치료 또는 예방을 위한 핵산
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
CN101663397B (zh) 2007-04-20 2015-04-22 宝生物工程株式会社 用于基因治疗的载体
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EP2318036B1 (de) 2008-06-30 2015-06-03 The Regents of the University of Michigan Aktivität von lysosomaler phospholipase a2 (lpla2) als diagnostisches und therapeutisches target zur identifizierung und behandlung von systemischem lupus erythematodes
KR101043871B1 (ko) * 2008-08-18 2011-06-22 가톨릭대학교 산학협력단 동종 제대혈 혈청 또는 혈장을 사용하는 유전자 도입 방법
WO2010080032A2 (en) * 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
EP2471901A4 (de) 2009-08-25 2013-06-26 Takara Bio Inc Verfahren zur herstellung einer t-zellen-population unter verwendung von retinsäure
US9228206B2 (en) 2010-06-30 2016-01-05 Takara Bio Inc. Method for gene transfer
CN102959080A (zh) 2010-06-30 2013-03-06 宝生物工程株式会社 用于基因转移的方法
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
WO2013045639A1 (en) * 2011-09-29 2013-04-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) LENTIVIRAL VECTORS PSEUDOTYPED WITH MUTANT BaEV GLYCOPROTEINS
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
DK3656869T4 (da) 2014-08-26 2025-05-19 Univ Leland Stanford Junior Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
DK3194602T3 (da) * 2014-09-18 2020-02-17 Univ Montreal Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
EP3455346A1 (de) 2016-05-12 2019-03-20 Erasmus University Medical Center Rotterdam Verfahren zur kultivierung myogener zellen, daraus erhaltene kulturen, screening-verfahren und zellkulturmedium
EP4342978A3 (de) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Goldoptimierte car-t-zellen
EP3580212A4 (de) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. Regulierung von chimären antigenrezeptoren
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
EP4043038A4 (de) 2019-10-11 2023-11-01 Takara Bio Inc. Sirna-expressionsvektor
KR102865366B1 (ko) 2019-12-30 2025-09-26 생-고뱅 퍼포먼스 플라스틱스 코포레이션 세포 형질 도입을 위한 컨테이너 및 방법
CN119470309B (zh) * 2025-01-08 2025-05-06 南京天纵易康生物科技股份有限公司 一种重组三型人源化胶原蛋白的细胞学检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198423A (en) * 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
AU687010B2 (en) * 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules

Also Published As

Publication number Publication date
KR20030097595A (ko) 2003-12-31
JPH09510874A (ja) 1997-11-04
US5686278A (en) 1997-11-11
JP3411039B2 (ja) 2003-05-26
MX9604240A (es) 1998-08-30
TWI232884B (en) 2005-05-21
JP2003111598A (ja) 2003-04-15
DE69535560T2 (de) 2008-04-30
AU2197995A (en) 1995-10-17
CN1177046C (zh) 2004-11-24
KR970702065A (ko) 1997-05-13
ES2294781T3 (es) 2008-04-01
KR100445712B1 (ko) 2004-11-26
CN1775946A (zh) 2006-05-24
CA2185712C (en) 2002-10-22
CN1152875A (zh) 1997-06-25
EP0752874A4 (de) 1999-05-12
CN100567488C (zh) 2009-12-09
WO1995026200A1 (en) 1995-10-05
EP0752874B1 (de) 2007-08-15
CA2185712A1 (en) 1995-10-05
JP3934005B2 (ja) 2007-06-20
AU690667B2 (en) 1998-04-30
EP1862546A1 (de) 2007-12-05
JP2003135086A (ja) 2003-05-13
RU2174846C2 (ru) 2001-10-20
DE69535560D1 (de) 2007-09-27
CN1775946B (zh) 2010-11-10
CN1632116A (zh) 2005-06-29
KR100506570B1 (ko) 2005-08-10
EP0752874A1 (de) 1997-01-15
JP2001169789A (ja) 2001-06-26

Similar Documents

Publication Publication Date Title
DE69535560D1 (de) Ein verstärkter, durch viren vermittelter dna-transfer
EP0873049A4 (de)
ATE198767T1 (de) Hantelförmige expressionskonstrukte für die gentherapie
PT900279E (pt) Processo melhorado de transformacao de plantas
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
ATE500323T1 (de) Subtilisin-variante
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
FI870343A7 (fi) Menetelmä geenien ilmentämiseksi kasveissa, kasvien osissa ja kasvisoluviljelmissä sekä menetelmässä käytettävät DNA-fragmentit, plasmidit ja transformoidut mikro-organismit
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
DE69834908D1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
FI934135A0 (fi) Ett foerfarande foer framstaellning av heme-proteiner
AU571128B2 (en) Expression of immunologically reactive aids viral protein
BR8108074A (pt) Sequencia de dna,plasmidio recombinante,ligadores de dna,cultura bacterial e processo para produzir taumatina
ATE299931T1 (de) Kaliumkanal-proteine zur verwendung in gentherapie zur verminderung von erektiler dysfunktion
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
DK628188A (da) Protein og fremgangsmaade til fremstilling deraf
ES8800350A1 (es) Procedimiento para preparar una cepa microbiana transformada mediante un plasmido recombinante.
BRPI0002694C1 (pt) processo de obtenção de vacina contra raiva em células vero, para uso humano
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
WO2001059139A3 (de) Ozon- und/oder pathogen-induzierbare genexpression in pflanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties